Home › NDC Lookup › RxCUI directory › RxCUI 2588070

Voxelotor 300 MG Tablet for Oral Suspension — RxCUI 2588070

RxNorm drug concept · Semantic clinical drug
RxCUI 2588070 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2588070
Official nameVoxelotor 300 MG Tablet for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped5
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Voxelotor: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Oxbryta works by latching onto the abnormal hemoglobin — called hemoglobin S — that causes red blood cells to sickle. By doing that, it helps keep your red blood cells rounder and...
  • What exactly does Oxbryta do for sickle cell disease?
  • You take it once a day by mouth — with or without food, whichever works best for you. If you're taking the regular tablet, swallow it whole; don't crush or chew it. If you have the...
  • The most common side effects are headache, diarrhea, stomach pain, nausea, rash, and fever — most are mild. The one to take seriously is a significant allergic reaction: if you dev...
📖 Read our full Voxelotor guide →

🕸️ Concept Web — How Voxelotor 300 MG Tablet for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Voxelotor 300 MG Tablet for Oral Suspension RxCUI 2588070

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Voxelotor 2265678
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Oxbryta 2265684
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Voxelotor Tablet for Oral Suspension 2588069
    • Voxelotor Oral Liquid Product 2588068
    • Voxelotor Oral Product 2265680
    • Voxelotor Tablet for Oral Suspension [Oxbryta] 2588073
    • Oxbryta Oral Liquid Product 2588072
    • Oxbryta Oral Product 2265687
    • Tablet for Oral Suspension 1861409
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Voxelotor 300 MG SCDC · 2588067
  • Voxelotor Tablet for Oral Suspension SCDF · 2588069
  • Voxelotor Oral Liquid Product SCDG · 2588068
  • Voxelotor Oral Product SCDG · 2265680

Brand-Name Concepts

  • Voxelotor 300 MG Tablet for Oral Suspension [Oxbryta] SBD · 2588074
  • Voxelotor 300 MG [Oxbryta] SBDC · 2588071
  • Voxelotor Tablet for Oral Suspension [Oxbryta] SBDF · 2588073
  • Oxbryta Oral Liquid Product SBDG · 2588072
  • Oxbryta Oral Product SBDG · 2265687
  • Oxbryta BN · 2265684

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 2588070 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72786-0101-01 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-101-01) OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2019-11-25
72786-0102-02 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-102-02) OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2022-10-14
72786-0102-03 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-102-03) OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2022-10-14
72786-0111-02 60 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-02... OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2021-12-17
72786-0111-03 90 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-03... OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2021-12-17
Observed labelers: Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.